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Misalignment between evidence-informed clinical care guideline rec-
ommendations and reimbursement policy has created care gaps that
lead to suboptimal outcomes for patients denied access to guideline-
based therapies. The purpose of this article is to make the case for
addressing this growing access barrier to optimal care. Stroke pre-
vention in atrial ﬁbrillation (AF) is discussed as an example. Stroke is
an extremely costly disease, imposing a signiﬁcant human, societal,
and economic burden. Stroke in the setting of AF carries an 80%
probability of death or disability. Although two-thirds of these strokesReceived for publication June 6, 2014. Accepted August 7, 2014.
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Le manque de concordance entre les recommandations formulees
dans les lignes directrices des soins cliniques fondees sur des donnees
probantes et les politiques de remboursement a cree des lacunes en
matière de soins qui entraînent des resultats sous-optimaux chez les
patients dont l’accès aux traitements bases sur les lignes directrices
est refuse. Le but de cet article est de faire en sorte que ces obstacles
à l’accès aux soins optimaux qui se font de plus en plus nombreux
soient surmontes. À titre d’exemple, nous traitons de la prevention de
l’accident vasculaire cerebral (AVC) associee à la ﬁbrillation auriculaireGiven recent economic circumstances, government payers feel
obliged to contain the rate of growth of public expenditures.
Cost and legal concerns tend to take precedence over scientiﬁc
considerations in bureaucratic policy decisions,1 resulting
in misalignment between evidence-informed clinical careguideline recommendations and reimbursement policy. Care
gaps are created when health care providers are unable to
consistently offer guideline-based therapies and this might
lead to suboptimal outcomes for patients denied access to
these therapies.
Lack of harmonization between reimbursement policy and
evidence-informed clinical care guideline recommendations
represents an increasing obstacle for the translation of
knowledge and its application in the clinical setting. The
purpose of this article is to make the case for addressing this
growing access barrier to optimal care. Opportunities for
improving stroke prevention in atrial ﬁbrillation (AF) are
discussed as an example.n Cardiovascular Society. This is an open access article under the CC BY-NC-
are preventable with appropriate anticoagulation, this has historically
been underprescribed and poorly managed. National and international
guidelines endorse the direct oral anticoagulants as ﬁrst-line therapy
for this indication. However, no Canadian province has provided these
agents with an unrestricted listing. These decisions appear to be
founded on silo-based cost assessmentdthe drug costs rather than
the total system costsdand thus overlook several important cost-
drivers in stroke. The discordance between best scientiﬁc evidence
and public policy requires health care providers to use a potentially
suboptimal therapy in contravention of guideline recommendations. It
represents a signiﬁcant obstacle for knowledge translation efforts that
aim to increase the appropriate anticoagulation of Canadians with AF.
As health care professionals, we have a responsibility to our patients to
engage with policy-makers in addressing and resolving this barrier to
optimal patient care.
(FA). L’AVC est une maladie qui coûte très cher et qui impose par
consequent un fardeau humain, social et economique important.
L’AVC qui survient dans le cadre de la ﬁbrillation auriculaire induit une
probabilite de mortalite ou d’incapacite estimee à 80 %. Bien que les
deux tiers de ces AVC puissent être evites par une anticoagulation
appropriee, ils ont traditionnellement fait l’objet d’une prescription
sous-optimale et d’une prise en charge mediocre. Les lignes directrices
nationales et internationales soutiennent que les anticoagulants oraux
directs comme traitement de première intention sont indiques.
Cependant, aucune province canadienne n’a fourni une liste non
restrictive de ces agents. Ces decisions semblent fondees sur
l’evaluation des coûts directs (les coûts des medicaments plutôt que
les coûts totaux du système) et, par consequent, omettent plusieurs
inducteurs importants de coûts lies à l’AVC. La discordance entre les
meilleures donnees scientiﬁques et les politiques publiques oblige les
fournisseurs de soins de sante à utiliser un traitement potentiellement
sous-optimal en ne tenant pas compte des recommandations for-
mulees dans les lignes directrices. Il represente un obstacle important
aux efforts de transmission des connaissances qui visent à accroître
l’utilisation de l’anticoagulation appropriee chez les Canadiens souf-
frant de FA. Comme professionnels de la sante, nous avons la
responsabilite envers nos patients de collaborer avec les responsables
de l’elaboration des politiques pour surmonter et resoudre ces obsta-
cles qui empêchent les patients d’avoir accès aux soins optimaux.
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Stroke is an extremely costly disease, imposing a signiﬁcant
human, societal, and economic burden. It strikes frequently,
often resulting in death or signiﬁcant disability, with profound
effects on individual quality of life and the functioning of
families and social networks.
Stroke and dementia are responsible for some of the
longest lengths of stay in Canadian hospitals. A recent Ca-
nadian stroke-costing study reported the average overall cost
of the ﬁrst year of stroke as $74,353.2 The initial 3 months
accounted for 54.5% of the overall costs and were driven
primarily by hospitalization and rehabilitation. Subsequently,
indirect costs such as rehabilitation, home care, and paid
caregivers represented the bulk of expenditures. Although
more difﬁcult to quantify than direct costs such as drugs and
acute hospitalization, and thus seldom considered in policy
decision-making, these latter costs contribute substantially to
the overall societal cost of stroke.
AF affects upwards of 1 in 10 people older than age 75
years and increases the risk of stroke ﬁvefold. Stroke in the
setting of AF carries an 80% probability of death or
disability. Two-thirds of these strokes are preventable with
appropriate anticoagulation, but this has historically been
underprescribed and poorly managed despite considerable
effort, with resultant signiﬁcant care gaps for the Canadian
population with AF.
National guidelines endorse the direct oral anticoagulants
(dabigatran, rivaroxaban, and apixaban) as being preferred
to warfarin for stroke prevention and reducing the risk
of intracranial bleeding, and hence the ﬁrst line therapy for
this indication.3 The Canadian Agency for Drugs and
Therapeutics in Health (CADTH) has recommended that
these agents receive reimbursement only if warfarin cannot
be used (eg, because of allergy) or after an initial attempt
with warfarin therapy has been unsuccessful (www.cadth.ca/en/products/cadth-overviews/overview-volume-3/3-2-02).
Provincial payers have uniformly adopted CADTH’s rec-
ommendations in their reimbursement guidelines; see
Supplemental Table S1.
This discordance between evidence and public policy pla-
ces health care providers in an awkward position. They are
required to treat many patients in a manner that is at variance
with national guidelines and this might have a deleterious
clinical effect in light of recent evidence of heightened risk of
both ischemic stroke and bleeding in the ﬁrst month of
initiating warfarin therapy (Supplemental Table S2). Some
patients will be able to access the preferred direct anticoagu-
lants if they have separate third-party coverage or are willing to
pay. But this effectively results in a 2-tiered level of care with
better stroke prevention for these individuals compared with
others who do not have supplemental coverage and are not
ﬁscally able to absorb the costs.
Removal of funding restrictions for evidence-based thera-
pies can be expected to increase utilization of these therapies
and thereby result in improved outcomes. Indeed, this has
been demonstrated in an Institute for Clinical Evaluative
Sciences study of cardiovascular outcomes after a change in
the prescription policy for clopidogrel.4 Removing the
requirement for previous authorization led to more timely
access to therapy and improved cardiovascular outcomes in
patients who required coronary stenting.
Harmonization between policy and evidence is an essential
and achievable goal. Acute stroke thrombolysis is a prime
example of how a therapy with a high unit cost can never-
theless have signiﬁcant clinical and health system beneﬁt,
including generalized cost-effectiveness through reducing
hospital and rehabilitation costs. Through collaboration be-
tween multiple specialties, support services, and government
agencies, trial results were translated into standardized systems
of care such as emergency room bypass protocols and hospital
Figure 1. Canadian Institutes of Health Research knowledge to action process. Reproduced from Canadian Institutes of Health Research
(http://www.cihr-irsc.gc.ca/e/39033.html#Knowledge-Users).
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and promulgated. Ministries of Health established policies
and set reimbursement and fee schedules to support imple-
mentation. This process of knowledge translation at multiple
levels has led to Canada boasting some of the highest rates of
acute stroke treatment in the world, being approximately 4
times higher than that in the United States.There Is a Better Way: A Call to Action
Knowledge translation initiatives have been implemented
across Canada that encourage all health care professionals
to collaboratively implement clinical care protocols for in-
dividuals with AF that are derived from evidence-informed
guidelines. The Canadian Institutes of Health Research has
developed a “Knowledge to Action Process” (Fig. 1) that de-
scribes the relationship between the creation of knowledge and
its application (www.cihr-irsc.gc.ca/e/39033.html#Knowledge-
Users). The “action cycle” around the central knowledge cre-
ation funnel represents activities needed for knowledge to be
applied. Assessment of barriers is an element of this cycle that
is particularly relevant to this discussion. Barriers can relate
to lack of knowledge regarding appropriate management or
be obstacles within the system of care. We believe that
misalignment between reimbursement policy and national
clinical care guidelines regarding stroke prevention in AF is asystem-based obstacle that is a priority to address. Despite a
strong base of scientiﬁc knowledge that serves as the foun-
dation for clinical guidelines, this lack of harmonization pre-
sents a signiﬁcant obstacle to the success of knowledge
translation activities.
It must be acknowledged that cost is not addressed in
evidence-based guidelines; in Canada, this has been a role
assumed by CADTH. In this example, CADTH appears to
have considered only direct costs (eg, drug acquisition, cost of
international normalized ratio management itself, treatment
costs for bleeding, and avoidable stroke) in its evaluation. A
more global assessment that includes opportunity costs (cost
of the outcome to the patient) and indirect costs (eg, costs
associated with undergoing international normalized ratio
assessment, lost productivity due to stroke, and longer-term
expenses of caring for individuals who have experienced
stroke) would seem more appropriate in this setting because
these costs are often signiﬁcant. Comprehensive cost effec-
tiveness analyses of the direct oral anticoagulants have been
published5; these analyses can provide valuable information to
assist policy-makers and, whenever available, should be taken
into account in funding decisions.
In its CanMEDS Physician Competency Framework, the
Royal College of Physicians and Surgeons of Canada lists 7
roles required of physicians, 1 of which is “health advocate”
(www.royalcollege.ca/portal/page/portal/rc/canmeds/framework).
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change speciﬁc practices or polices on behalf of those served.
Health advocacy is appropriately expressed both by individual
and collective actions of physicians in inﬂuencing public health
and policy.” Indeed, health advocacy is a responsibility also
shared by other health care providers. The physician’s role of
“Manager” in CanMEDS is also noted; a key competency
associated with this role is to “allocate ﬁnite health care re-
sources appropriately” by balancing effectiveness, efﬁciency,
and access with optimal care and by applying evidence and
management processes for cost-appropriate care.
The possibility of conﬂict between these 2 roles is recog-
nized in the CanMEDS Framework. However, we believe that
engaging with policy-makers to replace the silo-based cost
assessments currently used in policy decision-making with
system-based cost assessments is, in fact, necessary to effec-
tively fulﬁl both roles.Conclusions
As the population ages, the absolute number of Canadians
with AF will increase, resulting in an increased demand on
health services. In Canada, health care expenditures are the
single largest category of public expenses with a growth rate
that overshadows the rate of economic growth. System sus-
tainability is indeed threatened; but collapse is not inevitable.
It is within our personal and professional capacity to direct our
efforts at prevention of diseases such as stroke that have such
signiﬁcant human and economic consequences. Appropriate
anticoagulation of individuals with AF is an extremely effec-
tive means of accomplishing this.
Although knowledge translation efforts to address this need
and improve patient care are ongoing, misalignment between
evidence-informed guidelines and reimbursement policy rep-
resents a signiﬁcant obstacle. Removing this barrier to suc-
cessful knowledge translation would contribute greatly to
reducing AF-related stroke.
We all have a role to play in system sustainability and
patient accountability. As health care professionals, it is our
responsibility to interpret the best available evidence and
collaborate with policy-makers in applying the evidence to
formulate health policy. We must remember that we are here
to serve our patients. Cost containment is essential. However,
we must ensure that we consider a complete assessment of
costs when we make policy decisions and not limit the scope
to select budget silos. Silo-based cost assessments serve no one
welldnot patients, and not society. Furthermore, unilaterally
allowing cost considerations to trump the recommendations
of evidence-informed clinical practice guidelines forces healthcare providers into an ethically untenable clinical practice
environment in which they are required to prescribe therapies
they know to be subordinate to the scientiﬁcally validated
alternatives.
Finally, we must be diligent in fulﬁlling our responsibility
to patients to the best of our abilities. As health care pro-
fessionals, we can individually and collectively advocate for
enlightened public health and policy to improve the overall
health and well-being of Canadiansdindeed, we have an
obligation to do so.Funding Sources
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